Heart drug scrutiny after rise in mortality risk

Last week the European Medicines Agency (EMA) announced a review of the drug after preliminary findings from the SIGNIFY clinical trial revealed a small but significant increase in the combined risk of cardiovascular death and non-fatal MI in a subgroup of patients.